[Bio USA] SK Biopharmaceuticals doubles down on AI, open innovation
SK Biopharmaceuticals CEO Lee Dong-hoon announced the company is doubling down on AI and open innovation as core growth pillars, following a partnership with Insilico Medicine for AI-driven drug discovery. The company al…